title: [Combination of taxotere and doxorubicin in chemotherapy of disseminated breast cancer].
abstract: Chemotherapy (taxotere + doxorubicin) was given to 46 patients with disseminated breast cancer: first line--27 (group A) and second line (including treatment after anthracycline-containing combinations and taxol--19) (group B). Average effectiveness in group A was 70.4% (10/27); group B--42.1% (8/19). The highest response was shown by metastases to the lung, liver, peripheral lymph nodes and primary tumors; least response--metastases to bones and soft tissues. Remission duration ranged 3-26 months. Median remission duration in group A was significantly longer than in group B (13.3 +/- 1.0 and 7.0 +/- 1.4 months, respectively) (p(0 < 05). Remission is still on in 11 patients (more than 26 months). Toxic poisoning was moderate: neutropenia stage III-IV was reported in 82/225 cycles (36.4%) lasting more than 7 days in 4/225 cycles (1.7%), febrile neutropenia stage 1-II--10/225 cycles (4.4%); stomatitis and diarrhea stage III-IV--1/225 cycles (0.44%). Treatment was suspended because of hypertension in one patient. No other side effects stage III-IV were registered.
authors.affiliation: N.N. Blokhin Center for Oncology Research, Russian Academy of Medical Sciences, Moscow.
authors.forename: I V
authors.initials: IV
authors.lastname: Poddubnaia
authors.forename: L V
authors.initials: LV
authors.lastname: Manziuk
authors.forename: E V
authors.initials: EV
authors.lastname: Artamonova
authors.forename: T V
authors.initials: TV
authors.lastname: Arkad'eva
authors.forename: I S
authors.initials: IS
authors.lastname: Davidenko
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D043823:Taxoids; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D017239:Paclitaxel